344 related articles for article (PubMed ID: 33222700)
1. Regional binding of tau and amyloid PET tracers in Down syndrome autopsy brain tissue.
Lemoine L; Ledreux A; Mufson EJ; Perez SE; Simic G; Doran E; Lott I; Carroll S; Bharani K; Thomas S; Gilmore A; Hamlett ED; Nordberg A; Granholm AC
Mol Neurodegener; 2020 Nov; 15(1):68. PubMed ID: 33222700
[TBL] [Abstract][Full Text] [Related]
2. Characterization of MK6240, a tau PET tracer, in autopsy brain tissue from Alzheimer's disease cases.
Malarte ML; Nordberg A; Lemoine L
Eur J Nucl Med Mol Imaging; 2021 Apr; 48(4):1093-1102. PubMed ID: 32970217
[TBL] [Abstract][Full Text] [Related]
3. Discriminative binding of tau PET tracers PI2620, MK6240 and RO948 in Alzheimer's disease, corticobasal degeneration and progressive supranuclear palsy brains.
Malarte ML; Gillberg PG; Kumar A; Bogdanovic N; Lemoine L; Nordberg A
Mol Psychiatry; 2023 Mar; 28(3):1272-1283. PubMed ID: 36447011
[TBL] [Abstract][Full Text] [Related]
4. Cortical laminar tau deposits and activated astrocytes in Alzheimer's disease visualised by
Lemoine L; Saint-Aubert L; Nennesmo I; Gillberg PG; Nordberg A
Sci Rep; 2017 Apr; 7():45496. PubMed ID: 28374768
[TBL] [Abstract][Full Text] [Related]
5. Visualization of regional tau deposits using (3)H-THK5117 in Alzheimer brain tissue.
Lemoine L; Saint-Aubert L; Marutle A; Antoni G; Eriksson JP; Ghetti B; Okamura N; Nennesmo I; Gillberg PG; Nordberg A
Acta Neuropathol Commun; 2015 Jul; 3():40. PubMed ID: 26134112
[TBL] [Abstract][Full Text] [Related]
6. Comparative binding properties of the tau PET tracers THK5117, THK5351, PBB3, and T807 in postmortem Alzheimer brains.
Lemoine L; Gillberg PG; Svedberg M; Stepanov V; Jia Z; Huang J; Nag S; Tian H; Ghetti B; Okamura N; Higuchi M; Halldin C; Nordberg A
Alzheimers Res Ther; 2017 Dec; 9(1):96. PubMed ID: 29229003
[TBL] [Abstract][Full Text] [Related]
7. Amyloid, tau, and astrocyte pathology in autosomal-dominant Alzheimer's disease variants: AβPParc and PSEN1DE9.
Lemoine L; Gillberg PG; Bogdanovic N; Nennesmo I; Saint-Aubert L; Viitanen M; Graff C; Ingelsson M; Nordberg A
Mol Psychiatry; 2021 Oct; 26(10):5609-5619. PubMed ID: 32581318
[TBL] [Abstract][Full Text] [Related]
8. The relationships between neuroinflammation, beta-amyloid and tau deposition in Alzheimer's disease: a longitudinal PET study.
Ismail R; Parbo P; Madsen LS; Hansen AK; Hansen KV; Schaldemose JL; Kjeldsen PL; Stokholm MG; Gottrup H; Eskildsen SF; Brooks DJ
J Neuroinflammation; 2020 May; 17(1):151. PubMed ID: 32375809
[TBL] [Abstract][Full Text] [Related]
9. Imaging in-vivo tau pathology in Alzheimer's disease with THK5317 PET in a multimodal paradigm.
Chiotis K; Saint-Aubert L; Savitcheva I; Jelic V; Andersen P; Jonasson M; Eriksson J; Lubberink M; Almkvist O; Wall A; Antoni G; Nordberg A
Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1686-99. PubMed ID: 26996778
[TBL] [Abstract][Full Text] [Related]
10. Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease.
Maass A; Landau S; Baker SL; Horng A; Lockhart SN; La Joie R; Rabinovici GD; Jagust WJ;
Neuroimage; 2017 Aug; 157():448-463. PubMed ID: 28587897
[TBL] [Abstract][Full Text] [Related]
11. PET imaging of tau protein targets: a methodology perspective.
Lois C; Gonzalez I; Johnson KA; Price JC
Brain Imaging Behav; 2019 Apr; 13(2):333-344. PubMed ID: 29497982
[TBL] [Abstract][Full Text] [Related]
12. S-[18F]THK-5117-PET and [11C]PIB-PET Imaging in Idiopathic Normal Pressure Hydrocephalus in Relation to Confirmed Amyloid-β Plaques and Tau in Brain Biopsies.
Leinonen V; Rauramaa T; Johansson J; Bottelbergs A; Tesseur I; van der Ark P; Pemberton D; Koivisto AM; Jääskeläinen JE; Hiltunen M; Herukka SK; Blennow K; Zetterberg H; Jokinen P; Rokka J; Helin S; Haaparanta-Solin M; Solin O; Okamura N; Kolb HC; Rinne JO
J Alzheimers Dis; 2018; 64(1):171-179. PubMed ID: 29865068
[TBL] [Abstract][Full Text] [Related]
13. In vitro Characterization of the Regional Binding Distribution of Amyloid PET Tracer Florbetaben and the Glia Tracers Deprenyl and PK11195 in Autopsy Alzheimer's Brain Tissue.
Ni R; Röjdner J; Voytenko L; Dyrks T; Thiele A; Marutle A; Nordberg A
J Alzheimers Dis; 2021; 80(4):1723-1737. PubMed ID: 33749648
[TBL] [Abstract][Full Text] [Related]
14. Prodromal neuroinflammatory, cholinergic and metabolite dysfunction detected by PET and MRS in the TgF344-AD transgenic rat model of AD: a collaborative multi-modal study.
Chaney AM; Lopez-Picon FR; Serrière S; Wang R; Bochicchio D; Webb SD; Vandesquille M; Harte MK; Georgiadou C; Lawrence C; Busson J; Vercouillie J; Tauber C; Buron F; Routier S; Reekie T; Snellman A; Kassiou M; Rokka J; Davies KE; Rinne JO; Salih DA; Edwards FA; Orton LD; Williams SR; Chalon S; Boutin H
Theranostics; 2021; 11(14):6644-6667. PubMed ID: 34093845
[TBL] [Abstract][Full Text] [Related]
15. PET Imaging of Tau Pathology and Relationship to Amyloid, Longitudinal MRI, and Cognitive Change in Down Syndrome: Results from the Down Syndrome Biomarker Initiative (DSBI).
Rafii MS; Lukic AS; Andrews RD; Brewer J; Rissman RA; Strother SC; Wernick MN; Pennington C; Mobley WC; Ness S; Matthews DC;
J Alzheimers Dis; 2017; 60(2):439-450. PubMed ID: 28946567
[TBL] [Abstract][Full Text] [Related]
16. Novel 18F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease.
Okamura N; Furumoto S; Harada R; Tago T; Yoshikawa T; Fodero-Tavoletti M; Mulligan RS; Villemagne VL; Akatsu H; Yamamoto T; Arai H; Iwata R; Yanai K; Kudo Y
J Nucl Med; 2013 Aug; 54(8):1420-7. PubMed ID: 23857514
[TBL] [Abstract][Full Text] [Related]
17. Brain Amyloid-β Deposition and Blood Biomarkers in Patients with Clinically Diagnosed Alzheimer's Disease.
Li WW; Shen YY; Tian DY; Bu XL; Zeng F; Liu YH; Chen Y; Yao XQ; Li HY; Chen DW; Zhou FY; Yang H; Li QM; Bao WQ; Guan YH; Zhou HD; Jin RB; Wang YJ
J Alzheimers Dis; 2019; 69(1):169-178. PubMed ID: 30958377
[TBL] [Abstract][Full Text] [Related]
18. Tau PET Imaging for Staging of Alzheimer's Disease in Down Syndrome.
Rafii MS
Dev Neurobiol; 2019 Jul; 79(7):711-715. PubMed ID: 30536948
[TBL] [Abstract][Full Text] [Related]
19. Detection of Brain Tau Pathology in Down Syndrome Using Plasma Biomarkers.
Janelidze S; Christian BT; Price J; Laymon C; Schupf N; Klunk WE; Lott I; Silverman W; Rosas HD; Zaman S; Mapstone M; Lai F; Ances BM; Handen BL; Hansson O
JAMA Neurol; 2022 Aug; 79(8):797-807. PubMed ID: 35789365
[TBL] [Abstract][Full Text] [Related]
20. The Sensitivity of Tau Tracers for the Discrimination of Alzheimer's Disease Patients and Healthy Controls by PET.
Mohammadi Z; Alizadeh H; Marton J; Cumming P
Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
